The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - GlycoMimetics
GMI-1271, a novel E-selectin antagonist, in combination with chemotherapy in relapsed/refractory AML.
 
Daniel J. DeAngelo
Consulting or Advisory Role - Amgen; ARIAD; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Incyte; Novartis; Pfizer
 
Brian Andrew Jonas
Consulting or Advisory Role - Celgene; Rigel
Speakers' Bureau - Celgene; Incyte; Onyx
Research Funding - Abbvie (Inst); Daiichi Sankyo (Inst); Esanex (Inst); Genentech/Roche (Inst); Glycomimetics (Inst); KaloBios (Inst); Novartis (Inst); Pharmacyclics (Inst)
 
Jane Liesveld
Research Funding - GlycoMimetics
 
Michael O'Dwyer
Consulting or Advisory Role - Celgene; GlycoMimetics; Janssen
Research Funding - GlycoMimetics
 
Dale Bixby
No Relationships to Disclose
 
Anjali S. Advani
No Relationships to Disclose
 
Paula Marlton
Honoraria - Abbvie; Amgen; Janssen-Cilag; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Janssen-Cilag; Novartis; Pfizer; Roche; Takeda
Speakers' Bureau - Janssen-Cilag
Travel, Accommodations, Expenses - Roche; Takeda
 
John Magnani
Employment - GlycoMimetics
Leadership - GlycoMimetics
Stock and Other Ownership Interests - GlycoMimetics
Patents, Royalties, Other Intellectual Property - GlycoMimetics
 
Helen M. Thackray
Employment - GlycoMimetics
Stock and Other Ownership Interests - GlycoMimetics
 
Pamela S. Becker
No Relationships to Disclose